1
|
Huang YS: Recent progress in genetic
variation and risk of antituberculosis drug-induced liver injury. J
Chin Med Assoc. 77:169–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Zhang S, Pan H, Peng X, Lu H, Fan H, Zheng
X, Xu G, Wang M and Wang J: Preventive use of a hepatoprotectant
against anti-tuberculosis drug-induced liver injury: A randomized
controlled trial. J Gastroenterol Hepatol. 31:409–416. 2016.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Corsini A and Bortolini M: Drug-induced
liver injury: The role of drug metabolism and transport. J Clin
Pharmacol. 53:463–474. 2013. View
Article : Google Scholar : PubMed/NCBI
|
4
|
Hrycay EG and Bandiera SM: Involvement of
cytochrome P450 in reactive oxygen species formation and cancer.
Adv Pharmacol. 74:35–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Shahabi P, Siest G, Meyer UA and
Visvikis-Siest S: Human cytochrome P450 epoxygenases: Variability
in expression and role in inflammation-related disorders. Pharmacol
Ther. 144:134–161. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Feng FM, Guo M, Chen Y, Li SM, Zhang P,
Sun SF and Zhang GS: Genetic polymorphisms in metabolic enzymes and
susceptibility to anti-tuberculosis drug-induced hepatic injury.
Genet Mol Res. 13:9463–9471. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Turesky RJ and Le Marchand L: Metabolism
and biomarkers of heterocyclic aromatic amines in molecular
epidemiology studies: Lessons learned from aromatic amines. Chem
Res Toxicol. 24:1169–1214. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Rodenhiser D and Mann M: Epigenetics and
human disease: Translating basic biology into clinical
applications. CMAJ. 174:341–348. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Picascia A, Grimaldi V, Pignalosa O, De
Pascale MR, Schiano C and Napoli C: Epigenetic control of
autoimmune diseases: From bench to bedside. Clin Immunol. 157:1–15.
2015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Benakanakere M, Abdolhosseini M, Hosur K,
Finoti LS and Kinane DF: TLR2 promoter hypermethylation creates
innate immune dysbiosis. J Dent Res. 94:183–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Zeybel M, Hardy T, Robinson SM, Fox C,
Anstee QM, Ness T, Masson S, Mathers JC, French J, White S and Mann
J: Differential DNA methylation of genes involved in fibrosis
progression in non-alcoholic fatty liver disease and alcoholic
liver disease. Clin Epigenetics. 7:252015. View Article : Google Scholar : PubMed/NCBI
|
12
|
Dong Y, Zhao H, Li H, Li X and Yang S: DNA
methylation as an early diagnostic marker of cancer (Review).
Biomed Rep. 2:326–330. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Crary-Dooley FK, Tam ME, Dunaway KW,
Hertz-Picciotto I, Schmidt RJ and LaSalle JM: A comparison of
existing global DNA methylation assays to low-coverage whole-genome
bisulfite sequencing for epidemiological studies. Epigenetics.
12:206–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
14
|
He L, Gao L, Shi Z, Li Y, Zhu L, Li S,
Zhang P, Zheng G, Ren Q, Li Y, et al: Involvement of cytochrome
P450 1A1 and glutathione S-transferase P1 polymorphisms and
promoter hypermethylation in the progression of anti-tuberculosis
drug-induced liver injury: A case-control study. PLoS One.
10:e01194812015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Shen L, Zhang B, Sun S and Feng F:
Methylation of cytochrome p450 2E1 promoter induced by low dosage
of isoniazid. Environ Toxicol Pharmacol. 36:149–151. 2013.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhang B, Sun S, Shen L, Zu X, Chen Y, Hao
J, Huang X and Feng F: DNA methylation in the rat livers induced by
low dosage isoniazid treatment. Environ Toxicol Pharmacol.
32:486–490. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Akai S, Uematsu Y, Tsuneyama K, Oda S and
Yokoi T: Kupffer cell-mediated exacerbation of methimazole-induced
acute liver injury in rats. J Appl Toxicol. 36:702–715. 2016.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Takai S, Higuchi S, Yano A, Tsuneyama K,
Fukami T, Nakajima M and Yokoi T: Involvement of immune- and
inflammatory-related factors in flucloxacillin-induced liver injury
in mice. J Appl Toxicol. 35:142–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
19
|
Park SW, Kang JW and Lee SM: Role of
Kupffer cells in ischemic injury in alcoholic fatty liver. J Surg
Res. 194:91–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Bahari A, Mehrzad J, Mahmoudi M, Bassami
MR and Dehghani H: Cytochrome P450 isoforms are differently
up-regulated in aflatoxin B1-exposed human lymphocytes
and monocytes. Immunopharmacol Immunotoxicol. 36:1–10. 2014.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Mahmoud AM and Al Dera HS:
18β-Glycyrrhetinic acid exerts protective effects against
cyclophosphamide-induced hepatotoxicity: Potential role of PPARγ
and Nrf2 upregulation. Genes Nutr. 10:412015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Pogribny IP and Beland FA: DNA
hypomethylation in the origin and pathogenesis of human diseases.
Cell Mol Life Sci. 66:2249–2261. 2009. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ozden S, Kara Turgut N, Sezerman OU,
Durasi İM, Chen T, Demirel G, Alpertunga B, Chipman JK and Mally A:
Assessment of global and gene-specific DNA methylation in rat liver
and kidney in response to non-genotoxic carcinogen exposure.
Toxicol Appl Pharmacol. 289:203–212. 2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Meng H, Cao Y, Qin J, Song X, Zhang Q, Shi
Y and Cao L: DNA methylation, its mediators and genome integrity.
Int J Biol Sci. 11:604–617. 2015. View Article : Google Scholar : PubMed/NCBI
|
26
|
Mah WC and Lee CG: DNA methylation:
Potential biomarker in hepatocellular carcinoma. Biomark Res.
2:52014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Villanueva A, Portela A, Sayols S,
Battiston C, Hoshida Y, Méndez-González J, Imbeaud S, Letouzé E,
Hernandez-Gea V, Cornella H, et al: DNA methylation-based prognosis
and epidrivers in hepatocellular carcinoma. Hepatology.
61:1945–1956. 2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Kurzawski M, Dziedziejko V, Post M,
Wójcicki M, Urasińska E, Miętkiewski J and Droździk M: Expression
of genes involved in xenobiotic metabolism and transport in
end-stage liver disease: Up-regulation of ABCC4 and CYP1B1.
Pharmacol Rep. 64:927–939. 2012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Bernstein BE, Meissner A and Lander ES:
The mammalian epigenome. Cell. 128:669–681. 2007. View Article : Google Scholar : PubMed/NCBI
|
30
|
Tang W, Wang C, Fu F and Chen Q: RhoBTB2
gene in breast cancer is silenced by promoter methylation. Int J
Mol Med. 33:722–728. 2014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Ball MP, Li JB, Gao Y, Lee JH, LeProust
EM, Park IH, Xie B, Daley GQ and Church GM: Targeted and
genome-scale strategies reveal gene-body methylation signatures in
human cells. Nat Biotechnol. 27:361–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
32
|
Beedanagari SR, Taylor RT, Bui P, Wang F,
Nickerson DW and Hankinson O: Role of epigenetic mechanisms in
differential regulation of the dioxin-inducible human CYP1A1 and
CYP1B1 genes. Mol Pharmacol. 78:608–616. 2010. View Article : Google Scholar : PubMed/NCBI
|
33
|
Ingelman-Sundberg M, Zhong XB, Hankinson
O, Beedanagari S, Yu AM, Peng L and Osawa Y: Potential role of
epigenetic mechanisms in the regulation of drug metabolism and
transport. Drug Metab Dispos. 41:1725–1731. 2013. View Article : Google Scholar : PubMed/NCBI
|
34
|
Marques M, Laflamme L and Gaudreau L:
Estrogen receptor α can selectively repress dioxin
receptor-mediated gene expression by targeting DNA methylation.
Nucleic Acids Res. 41:8094–8106. 2013. View Article : Google Scholar : PubMed/NCBI
|
35
|
Gao K, Brandt I, Goldstone JV and Jönsson
ME: Cytochrome P450 1A, 1B, and 1C mRNA induction patterns in
three-spined stickleback exposed to a transient and a persistent
inducer. Comp Biochem Physiol C Toxicol Pharmacol. 154:42–55. 2011.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Tokizane T, Shiina H, Igawa M, Enokida H,
Urakami S, Kawakami T, Ogishima T, Okino ST, Li LC, Tanaka Y, et
al: Cytochrome P450 1B1 is overexpressed and regulated by
hypomethylation in prostate cancer. Clin Cancer Res. 11:5793–5801.
2005. View Article : Google Scholar : PubMed/NCBI
|
37
|
Zhao Y, Ma X, Wang J, He X, Hu Y, Zhang P,
Wang R, Li R, Gong M, Luo S and Xiao X: Curcumin protects against
CCl4-induced liver fibrosis in rats by inhibiting HIF-1α through an
ERK-dependent pathway. Molecules. 19:18767–18780. 2014. View Article : Google Scholar : PubMed/NCBI
|
38
|
Qian H, Shi J, Fan TT, Lv J, Chen SW, Song
CY, Zheng ZW, Xie WF and Chen YX: Sophocarpine attenuates liver
fibrosis by inhibiting the TLR4 signaling pathway in rats. World J
Gastroenterol. 20:1822–1832. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Zhang F, Wang X, Qiu X, Wang J, Fang H,
Wang Z, Sun Y and Xia Z: The protective effect of esculentoside A
on experimental acute liver injury in mice. PLoS One.
9:e1131072014. View Article : Google Scholar : PubMed/NCBI
|